[go: up one dir, main page]

MX2018004988A - Moleculas de union que inhibe el crecimiento de cancer. - Google Patents

Moleculas de union que inhibe el crecimiento de cancer.

Info

Publication number
MX2018004988A
MX2018004988A MX2018004988A MX2018004988A MX2018004988A MX 2018004988 A MX2018004988 A MX 2018004988A MX 2018004988 A MX2018004988 A MX 2018004988A MX 2018004988 A MX2018004988 A MX 2018004988A MX 2018004988 A MX2018004988 A MX 2018004988A
Authority
MX
Mexico
Prior art keywords
binding molecules
cancer growth
inhibit cancer
antibodies
extracellular part
Prior art date
Application number
MX2018004988A
Other languages
English (en)
Other versions
MX389547B (es
Inventor
Throsby Mark
Carolus Clevers Johannes
Logtenberg Ton
Gerhardus Jacob Vries Robert
Batlle Eduard
Herpers Bram
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2018004988A publication Critical patent/MX2018004988A/es
Publication of MX389547B publication Critical patent/MX389547B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención proporciona medios y métodos para inhibir el crecimiento de un cáncer. Los medios en algunas modalidades, comprenden proteínas y anticuerpos que unen una parte extracelular de un miembro asociado a la membrana de la familia del receptor de factor de crecimiento epidérmico (EGF) y una parte extracelular de un miembro asociado a la membrana de una ruta de señalización de WNT. Además, se proporcionan diversas células y ensayos que son útiles para la producción de las proteínas, anticuerpos y células.
MX2018004988A 2015-10-23 2016-10-21 Moleculas de union que inhibe el crecimiento de cancer. MX389547B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15191343 2015-10-23
EP16168647 2016-05-06
PCT/NL2016/050726 WO2017069628A2 (en) 2015-10-23 2016-10-21 Binding molecules that inhibit cancer growth

Publications (2)

Publication Number Publication Date
MX2018004988A true MX2018004988A (es) 2018-11-09
MX389547B MX389547B (es) 2025-03-20

Family

ID=57190021

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004988A MX389547B (es) 2015-10-23 2016-10-21 Moleculas de union que inhibe el crecimiento de cancer.
MX2022000302A MX2022000302A (es) 2015-10-23 2018-04-23 Moleculas de union que inhiben el crecimiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000302A MX2022000302A (es) 2015-10-23 2018-04-23 Moleculas de union que inhiben el crecimiento del cancer.

Country Status (26)

Country Link
US (2) US11939394B2 (es)
EP (2) EP3365373B1 (es)
JP (3) JP7296728B2 (es)
KR (2) KR102877714B1 (es)
CN (2) CN115925944A (es)
AU (2) AU2016340764B2 (es)
BR (1) BR112018008068A2 (es)
CA (1) CA3002957A1 (es)
CY (1) CY1124108T1 (es)
DK (1) DK3365373T3 (es)
EA (1) EA201890866A1 (es)
ES (1) ES2865482T3 (es)
HR (1) HRP20210483T1 (es)
HU (1) HUE055222T2 (es)
LT (1) LT3365373T (es)
MA (2) MA45517B1 (es)
MD (1) MD3365373T2 (es)
MX (2) MX389547B (es)
NZ (1) NZ742290A (es)
PL (1) PL3365373T3 (es)
RS (1) RS61800B1 (es)
SG (1) SG11201803359VA (es)
SI (1) SI3365373T1 (es)
SM (1) SMT202100230T1 (es)
WO (1) WO2017069628A2 (es)
ZA (1) ZA201802758B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
EP3365373B1 (en) * 2015-10-23 2021-03-10 Merus N.V. Binding molecules that inhibit cancer growth
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
AU2018207440B2 (en) * 2017-01-11 2022-06-02 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (RSPO) surrogate molecules
CA3050133A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3600411A1 (en) * 2017-03-31 2020-02-05 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
KR102905513B1 (ko) 2017-03-31 2026-01-02 메뤼스 엔.페. NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
IL271832B2 (en) * 2017-07-06 2025-07-01 Merus Nv Bispecific anti pd1-anti tim3 antibodies and uses thereof
CA3068933A1 (en) * 2017-07-06 2019-01-10 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
FI3665198T3 (fi) 2017-08-09 2025-04-25 Merus Nv EGFR:ää ja cMET:tä sitovia vasta-aineita
KR20200139189A (ko) * 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
WO2020014271A1 (en) * 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses
AU2019416324A1 (en) * 2018-12-27 2021-07-22 H. Lee Moffitt Cancer Center And Research Institute Inc. Bispecific antibody for membrane clearance of target receptors
BR112021013009A2 (pt) * 2018-12-31 2021-09-14 Merus N.V. Domínios de ligação mistos
US20220380440A1 (en) 2018-12-31 2022-12-01 Merus N.V. Truncated multivalent multimers
CA3130248A1 (en) * 2019-02-14 2020-08-20 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3.
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
PH12021552030A1 (en) 2019-02-26 2022-08-15 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
TW202509079A (zh) * 2019-04-04 2025-03-01 日商小野藥品工業股份有限公司 雙特異性抗體
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
MX2022002096A (es) 2019-08-19 2022-03-17 Merus Nv Tratamiento del cancer con una combinacion de un anticuerpo que se une al receptor 5 acoplado a la proteina g que contiene repeticiones ricas en leucina (lgr5) y al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de topoisomerasa i.
CA3159745A1 (en) * 2019-11-01 2021-05-06 The Regents Of The University Of California Degradation of surface proteins using bispecific binding agent
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
JP2023517010A (ja) * 2020-03-05 2023-04-21 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー タンパク質分解を標的とする膜ユビキチンリガーゼ
KR20230005281A (ko) * 2020-04-24 2023-01-09 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
EP4168442A1 (en) * 2020-06-18 2023-04-26 UMC Utrecht Holding B.V. Screening method for effective target - e3 ligase combinations
CN113862326B (zh) * 2020-09-08 2024-07-05 复旦大学 KREMEN1和/或ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用
JP7714992B2 (ja) * 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
KR20230109668A (ko) 2020-11-16 2023-07-20 서로젠 오퍼레이팅, 인크. 간-특이적 Wnt 신호 증강 분자 및 그의 용도
TW202237656A (zh) * 2020-12-15 2022-10-01 荷蘭商美勒斯公司 利用結合ｌｇｒ５與ｅｇｆｒ之抗體治療癌症
WO2022131918A1 (en) 2020-12-18 2022-06-23 Merus N.V. Antibody composition
CN114853889B (zh) * 2021-02-03 2024-03-01 中国科学院动物研究所 针对人gpr48的单克隆抗体及其应用
CA3211727A1 (en) * 2021-03-31 2022-10-06 Merus N.V. Novel pd-1 binding domains
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
CN118055949A (zh) 2021-10-06 2024-05-17 美勒斯公司 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
WO2024136658A1 (en) 2022-12-23 2024-06-27 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
IL321816A (en) 2022-12-28 2025-08-01 Merus Nv Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
CN116082510B (zh) * 2023-03-07 2023-12-05 四川尚锐生物医药有限公司 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
JP3502093B2 (ja) 1991-07-15 2004-03-02 ザ・ウエルカム・ファウンデーション・リミテッド 抗体の製造
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 E. Missel GmbH & Co., 70374 Stuttgart Trägersystem für Bade-, Dusch- oder Whirlwannen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
SI1161548T2 (sl) 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
EP1600510B1 (en) 2001-07-04 2007-03-28 Chromagenics B.V. DNA sequences having anti-repressor activity
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2155788B1 (en) 2007-04-03 2012-06-27 Micromet AG Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
CA2715043C (en) 2008-02-05 2021-02-16 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
CA2729095C (en) 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
EP2389392A1 (en) 2009-01-26 2011-11-30 Genmab A/S Methods for producing mixtures of antibodies
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG178509A1 (en) 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011056124A1 (en) 2009-11-04 2011-05-12 Affibody Ab Her3 binding polypeptides
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PL2501817T5 (pl) 2010-02-08 2021-08-16 Regeneron Pharmaceuticals, Inc. Mysz o wspólnym łańcuchu lekkim
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
ES2537207T3 (es) 2010-08-16 2015-06-03 Novimmune S.A. Métodos para la generación de anticuerpos multiespecíficos y multivalentes
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
US20140056898A1 (en) 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
KR20200052383A (ko) 2011-03-25 2020-05-14 아이크노스 사이언스 에스. 아. 헤테로 이량체 면역글로불린
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
PL2707391T3 (pl) 2011-05-13 2018-04-30 Gamamabs Pharma Przeciwciała przeciwko her3
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
CN106167526A (zh) * 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
ES2745684T3 (es) 2011-11-23 2020-03-03 Medimmune Llc Moléculas de unión específicas para HER3 y usos de las mismas
UY34488A (es) 2011-12-05 2013-07-31 Novartis Ag Anticuerpos dirigidos al receptor de factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3
WO2013084147A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
WO2013134686A1 (en) 2012-03-09 2013-09-12 Promega Corporation pH SENSORS
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
PT2900694T (pt) 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
US10093740B2 (en) 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
ES2700231T3 (es) * 2012-11-21 2019-02-14 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US20160319034A1 (en) * 2013-03-14 2016-11-03 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
JP6402173B2 (ja) 2013-04-05 2018-10-10 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
HRP20240939T1 (hr) * 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
ES3006007T3 (en) 2014-02-28 2025-03-17 Merus Nv Antibody that binds erbb-2 and erbb-3
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
AU2015229591B2 (en) * 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
EA201890028A1 (ru) 2015-07-10 2018-08-31 Мерус Н.В. Антитело, связывающее cd3 человека
EP3365373B1 (en) * 2015-10-23 2021-03-10 Merus N.V. Binding molecules that inhibit cancer growth
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3600411A1 (en) 2017-03-31 2020-02-05 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
KR102905513B1 (ko) 2017-03-31 2026-01-02 메뤼스 엔.페. NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
FI3665198T3 (fi) 2017-08-09 2025-04-25 Merus Nv EGFR:ää ja cMET:tä sitovia vasta-aineita
WO2020140084A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof

Also Published As

Publication number Publication date
MA45517A (fr) 2018-08-29
ES2865482T3 (es) 2021-10-15
EA201890866A1 (ru) 2018-09-28
MX2022000302A (es) 2022-02-03
WO2017069628A9 (en) 2017-10-26
CN108602888B (zh) 2022-10-04
EP3365373A2 (en) 2018-08-29
JP2023008754A (ja) 2023-01-19
BR112018008068A2 (en) 2018-11-13
ZA201802758B (en) 2020-08-26
SG11201803359VA (en) 2018-05-30
HRP20210483T1 (hr) 2021-07-09
NZ759325A (en) 2025-05-30
DK3365373T3 (da) 2021-04-06
CN108602888A (zh) 2018-09-28
CN115925944A (zh) 2023-04-07
AU2023222928A1 (en) 2023-09-21
JP7296728B2 (ja) 2023-06-23
NZ742290A (en) 2019-11-29
WO2017069628A2 (en) 2017-04-27
JP2019500405A (ja) 2019-01-10
HUE055222T2 (hu) 2021-11-29
PL3365373T3 (pl) 2021-08-23
RS61800B1 (sr) 2021-06-30
WO2017069628A3 (en) 2017-09-08
KR20250157457A (ko) 2025-11-04
EP3912998A3 (en) 2022-02-23
HK1253914A1 (en) 2019-07-05
KR20180100305A (ko) 2018-09-10
CY1124108T1 (el) 2022-05-27
MA54760A (fr) 2022-04-13
MX389547B (es) 2025-03-20
US20180312604A1 (en) 2018-11-01
CA3002957A1 (en) 2017-04-27
KR102877714B1 (ko) 2025-10-29
EP3912998A2 (en) 2021-11-24
AU2016340764B2 (en) 2023-06-01
JP2024023445A (ja) 2024-02-21
SMT202100230T1 (it) 2021-07-12
LT3365373T (lt) 2021-05-25
US11939394B2 (en) 2024-03-26
SI3365373T1 (sl) 2021-08-31
EP3365373B1 (en) 2021-03-10
US20240343824A1 (en) 2024-10-17
MD3365373T2 (ro) 2021-08-31
MA45517B1 (fr) 2021-04-30
AU2016340764A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2018004988A (es) Moleculas de union que inhibe el crecimiento de cancer.
MX2022011472A (es) Formato de anticuerpo multiespecifico heterodimerico.
CO2019001980A2 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CL2019002824A1 (es) Anticuerpos anti-lag3.
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
CO2017010618A2 (es) Anticuerpos contra icos
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
MX2019008359A (es) Cadena j modificada.
BR112016028644A2 (pt) composições de célula t aprimoradas
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX2016016886A (es) Anticuerpos anti-axl.
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
MX2016009911A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe
CO2017010143A2 (es) Procesos para preparar fluorocetólidos
EP3717825A4 (en) WEIGHTED FLOW MULTI-SOURCE COMPOSITE SAMPLE SYSTEM
BR112019000775A2 (pt) composições e métodos para marcar composições de hidrocarboneto com corantes não-mutagênicos
EA201991922A1 (ru) Сконструированные полипептиды, связывающие трансферриновый рецептор